Every 10-Q that Anavex Life Sciences (AVXL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVXL filings page.
ANAVEX LIFE SCIENCES CORP. (AVXL) reported a sharp improvement in results for the quarter ended June 30, 2026, driven by large reversals of share-based compensation after the former CEO’s termination. Operating expenses turned into a $6.7 million recovery versus $14.5 million of expenses a year earlier, and net income was $7.8 million (basic and diluted $0.08 per share) compared with a $13.2 million loss. For the nine months, the company posted a $3.2 million net loss versus $36.6 million previously.
Cash and cash equivalents were $118.3 million at June 30, 2026, up from $102.6 million, helped by $36.4 million in net ATM sales under a $150 million 2025 Sales Agreement; management expects this to fund operations into mid to late fiscal 2028. AVXL remains a clinical-stage CNS company with no revenue, now prioritizing ANAVEX 2‑73 (blarcamesine) in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome while pausing other programs.
The company discloses a material weakness in internal control over financial reporting tied to prior concentration of non-financial information with the former CEO and acknowledges Nasdaq non-compliance due to late 10-Q filings, with a compliance plan under review. A prior Alzheimer’s MAA in Europe was withdrawn after a negative CHMP assessment, and multiple legal matters, including actions involving the former CEO, are ongoing.
ANAVEX LIFE SCIENCES CORP. (AVXL) reported a smaller loss for the quarter ended March 31, 2026 as it refocused its CNS drug pipeline on lead asset ANAVEX 2-73 (blarcamesine) in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome.
Cash and cash equivalents were $127.4 million, up from $102.6 million at September 30, 2025, driven by issuing 6,026,237 shares under a $150 million at-the-market sales agreement for net proceeds of about $36.4 million. Working capital was $121.7 million, and management currently expects this to fund operations into mid to late fiscal 2028.
Quarterly net loss narrowed to $5.3 million (vs. $11.2 million a year earlier), mainly from cutting research and development spending. The company remains pre-revenue, disclosed a material weakness in internal control over financial reporting, faces Nasdaq listing deficiency for late SEC filings, and is involved in litigation related to the former CEO’s termination.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an Amendment No. 1 to its Form 10‑Q for the quarter ended December 31, 2025. After a review overseen by a special committee and the Audit Committee, management reassessed disclosure controls and internal control over financial reporting as of that date.
The company concluded that, due to a previously identified material weakness in internal control over financial reporting that existed at September 30, 2025 and had not been remediated, its disclosure controls and procedures and internal control over financial reporting were not effective as of December 31, 2025. Management nevertheless determined that the condensed consolidated interim financial statements for the quarter are fairly presented in accordance with U.S. GAAP, so no restatement is being made in this amendment. The material weakness was identified after the quarter, and remediation planning began later, as described in the Form 10‑K/A for the year ended September 30, 2025.
Anavex Life Sciences Corp. reported a narrower net loss for the three months ended December 31, 2025 as it continued developing CNS drug candidates without generating product revenue. Net loss was $5.7 million, improved from $12.1 million a year earlier, driven by sharply lower research and development and general and administrative expenses.
Operating expenses fell to $6.8 million from $13.6 million, reflecting reduced clinical trial and share-based compensation costs. Other income of $1.1 million, mainly interest on cash, partly offset expenses. Anavex strengthened its balance sheet by raising $36.3 million through its 2025 at-the-market Sales Agreement, issuing about 6.0 million new shares.
Cash and cash equivalents rose to $131.7 million as of December 31, 2025, up from $102.6 million at September 30, 2025. Management states this working capital should fund operations for more than 12 months, even as the company expects continued negative operating cash flows while advancing programs in Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other CNS indications.
Anavex Life Sciences (AVXL) reported continued clinical progress alongside ongoing operating losses. The company held $101.164 million in cash and cash equivalents at June 30, 2025 and management believes current working capital is sufficient to meet requirements beyond the next 12 months. For the nine months ended June 30, 2025 the company reported a net loss of $36.55 million and used $30.44 million of cash in operations, increasing the accumulated deficit to $372.6 million. Clinical highlights include statistically significant results from its Phase 2b/3 ANAVEX4 2-73 trial in early Alzheimers disease (ADAS-Cog13 and CDR-SB improvements, with dose-group comparisons reported) and an MAA for blarcamesine accepted by the EMA for scientific review. Subsequent to period end the company entered a $150 million at-the-market Sales Agreement with TD Securities, providing an additional capital-raising vehicle. The company disclosed a $1.0 million Michael J. Fox Foundation research grant and noted tax incentive receivables subject to potential ATO review.